Drug intelligence / Profile preview

anastrozole + trastuzumab

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous, Subcutaneous

Overview

Anastrozole + trastuzumab is a combination therapy used for the treatment of HER2-positive, hormone receptor-positive breast cancer. Anastrozole is an aromatase inhibitor that works by decreasing estrogen production and suppressing the growth of tumors that need estrogen to grow. Trastuzumab is a monoclonal antibody that selectively binds to the extracellular domain of the human epidermal growth factor receptor protein (HER2) and suppresses cancer cell growth, proliferation, and survival. This combination targets both the hormone receptor and HER2 pathways in breast cancer cells.

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)CYP19A1 (Aromatase)

Beyond the preview

Go deeper on anastrozole + trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anastrozole + trastuzumab.

Explore the full profile